Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?

Basit Öğe Kaydı
dc.authoridKanıtez, Nilüfer Alpay/0000-0003-1185-5816
dc.authoridKaradag, Omer/0000-0002-3443-3117
dc.authoridGonullu, Emel/0000-0002-6990-4206
dc.authoridErden, Abdulsamet/0000-0002-8084-2018
dc.authoridkucuksahin, orhan/0000-0003-4530-2304
dc.authoridAkar, Servet/0000-0002-3734-1242
dc.authoridATAGUNDUZ, MEHMET PAMIR/0000-0002-6393-7461
dc.authorwosidYazisiz, Veli/C-1808-2016
dc.authorwosidKanıtez, Nilüfer Alpay/W-7332-2019
dc.authorwosidKaradag, Omer/AAD-5448-2019
dc.authorwosidGonullu, Emel/AAK-7851-2021
dc.authorwosidAteş, Aşkın/HJI-6996-2023
dc.authorwosidilgen, ufuk/R-8761-2017
dc.authorwosidErden, Abdulsamet/W-2397-2019
dc.contributor.authorIlgen, Ufuk
dc.contributor.authorKaradag, Omer
dc.contributor.authorEmmungil, Hakan
dc.contributor.authorKucuksahin, Orhan
dc.contributor.authorKoca, Suleyman Serdar
dc.contributor.authorErden, Abdulsamet
dc.contributor.authorBes, Cemal
dc.date.accessioned2024-06-12T10:52:32Z
dc.date.available2024-06-12T10:52:32Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThis study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in a Bacillus Calmette-Guerin-vaccinated population. Adult RA (n = 206) and SpA (n = 392) patients from the TReasure database who had both TST and QFT-GIT prior to initiation of biological and targeted synthetic DMARDs were included in the study. Demographic and disease characteristics along with pre-biologic DMARD and steroid use were recorded. The distribution of TST and performance with respect to QFT-GIT were compared between RA and SpA groups. Pre-biologic conventional DMARD and steroid use was higher in the RA group. TST positivity rates were 44.2% in RA and 69.1% in SpA for a 5 mm cutoff (p < 0.001). Only 8.9% and 15% of the patients with RA and SpA, respectively, tested positive by QFT-GIT. The two tests poorly agreed in both groups at a TST cutoff of 5 mm and increasing the TST cutoff only slightly increased the agreement. Among age, sex, education and smoking status, pre-biologic steroid and conventional DMARD use, disease group, and QFT-GIT positivity, which were associated with a 5 mm or higher TST, only disease group (SpA) and QFT-GIT positivity remained significant in multiple logistic regression. TST positivity was more pronounced in SpA compared to that in RA and this was not explainable by pre-biologic DMARD and steroid use. The agreement of TST with QFT-GIT was poor in both groups. Using a 5 mm TST cutoff for both diseases could result in overestimating LTBI in SpA.en_US
dc.identifier.doi10.1007/s00296-022-05134-z
dc.identifier.endpage1806en_US
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.issue10en_US
dc.identifier.pmid35486197en_US
dc.identifier.scopus2-s2.0-85129018736en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1797en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-022-05134-z
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18751
dc.identifier.volume42en_US
dc.identifier.wosWOS:000788942000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofRheumatology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectArthritisen_US
dc.subjectSpondyloarthritisen_US
dc.subjectInterferon-Gamma Release Testsen_US
dc.subjectTuberculin Testen_US
dc.subjectLatent Tuberculosisen_US
dc.subjectGamma Release Assaysen_US
dc.subjectClinical-Practice Guidelinesen_US
dc.subjectQuantiferon-Tb-Golden_US
dc.subjectLatent Tuberculosisen_US
dc.subjectRheumatoid-Arthritisen_US
dc.subjectClassification Criteriaen_US
dc.subjectActive Tuberculosisen_US
dc.subjectItalian Societyen_US
dc.subjectDisease-Controlen_US
dc.subjectInfectionen_US
dc.titleTuberculin skin test before biologic and targeted therapies: does the same rule apply for all?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu